Incretin: Physiology and What Research Reports

What the term "incretin" means

Incretin is a collective label for gut-derived hormones that are secreted in response to nutrient intake and that increase insulin release from pancreatic beta cells in a glucose-dependent manner. A 2018 review described glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) as the two hormones that satisfy this classical definition and outlined their roles in health and disease (PMID 29364588). A 2013 review in Cell Metabolism reported that both peptides are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which gives them very short circulating half-lives and shaped the pharmacology built around them (PMID 23684623).

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or treatment. It summarises what published papers reported about incretin physiology and does not describe protocols, regimens or personal use of any compound.

Where incretin hormones are produced

Incretins are products of enteroendocrine cells scattered through the intestinal epithelium. A 2013 review reported that GIP is secreted mainly from K cells of the proximal small intestine while GLP-1 is secreted mainly from L cells that are more abundant in the distal gut, with both responding to ingested nutrients (PMID 23684623). A 2023 review described how this enteroendocrine biology has been extended by newer work on receptor distribution and on peptides that act at more than one incretin receptor (PMID 36976349).

Mechanisms of secretion remain an active research area. A 2024 study reported that potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies, framing ion-channel control of enteroendocrine cells as a route to stimulating endogenous hormone release (PMID 39128897). A 2025 review reported that sleep and circadian factors also influence the incretin system, adding timing of nutrient intake and rest to the list of variables researchers consider (PMID 40933800).

What incretin hormones do in the body

• Glucose-dependent insulin secretion. A 2013 review reported that GIP and GLP-1 potentiate insulin release from beta cells only when glucose is elevated, a property central to their physiology and pharmacology (PMID 23684623).
• Glucagon and islet signalling. A 2021 pathophysiological update reported that GLP-1 and GIP differ in their effects on alpha-cell glucagon secretion, and reviewed how these differences matter in metabolic and cardiovascular disease (PMID 34310013).
• Gastric emptying and food intake. A 2018 review described GLP-1 actions extending beyond the islet, including slowing of gastric emptying and reduction of food intake (PMID 29364588).
• Actions outside the pancreas. A 2023 review reported that incretin receptors are expressed in multiple tissues, with GIP signalling in adipose tissue and bone among the areas discussed in what its authors called an expanding incretin universe (PMID 36976349).
• Skeletal muscle. A 2025 review examined the impact of incretin-based therapy on skeletal muscle health, reporting that muscle and lean-mass outcomes have become a focus of research alongside glycaemic and weight endpoints (PMID 41011082).

The "incretin effect" and how it is measured

The phrase incretin effect has a specific experimental meaning. A 2016 review in The Lancet Diabetes & Endocrinology described the incretin effect as the larger insulin response observed after oral glucose compared with intravenous glucose given to match the same blood glucose profile, and reported that this effect is diminished in people with type 2 diabetes (PMID 26876794). A 2023 review in Diabetologia likewise discussed the relationship between incretin hormones and type 2 diabetes, including whether a reduced incretin effect is a cause or a consequence of the disease (PMID 37430117).

The 2016 review also reported that the incretin effect has been studied in relation to therapeutic interventions, meaning the same oral-versus-intravenous paradigm is used to ask whether treatments change gut hormone signalling (PMID 26876794).

Terminology researchers use

How incretin biology moved into pharmacology

Because native incretins are short-lived, researchers pursued two broad strategies. A 2006 Lancet seminar reported that GLP-1 receptor agonists and DPP-4 inhibitors both exploit the incretin system in type 2 diabetes, one by providing degradation-resistant receptor activation and the other by limiting breakdown of endogenous hormones (PMID 17098089). A 2015 clinical review summarised incretin-based therapies as a distinct class within diabetes care (PMID 25456646), and a 2022 Danish review discussed incretin-based therapy of metabolic disease more broadly, beyond glucose lowering alone (PMID 36629298).

A 2023 review reported that the field has expanded from single-hormone mimicry towards molecules engaging more than one receptor, and framed this as the translation of basic incretin biology into clinical development (PMID 36976349).

Incretin-Based Therapies: What Studies Report

Reviews of this drug class discuss tolerability alongside efficacy rather than treating incretin pharmacology as effect-free. The 2006 Lancet seminar reviewed GLP-1 receptor agonists and DPP-4 inhibitors together with their safety and tolerability considerations in type 2 diabetes (PMID 17098089), and a 2015 review of incretin-based therapies similarly covered the clinical profile of these agents (PMID 25456646). A 2025 review reported that skeletal muscle health is one area where researchers have asked whether incretin-based treatment carries trade-offs alongside metabolic benefit (PMID 41011082). Specific event rates are not reproduced here; readers who want frequency data can read the cited papers and current prescribing information, and clinical questions belong with a licensed physician.

Why the term matters to readers of peptide literature

Many peptides discussed online are described in relation to incretin signalling, so the vocabulary recurs constantly: incretin, incretin mimetic, incretin effect, GIP/GLP-1 receptor. A 2021 update reported that incretin research now spans metabolic and cardiovascular pathophysiology rather than glucose control alone (PMID 34310013), and a 2018 review reported that incretin biology is relevant to both health and disease states (PMID 29364588). Understanding the definition makes it easier to see when a source is describing a hormone, an experimental measurement, or an approved drug class — three different things that share one word. Research-use-only materials and unapproved preparations are not equivalent to approved medicines, and nothing on this page describes personal use.

References

• Incretin hormones: Their role in health and disease (Diabetes, Obesity & Metabolism, 2018)
• Incretin hormones and type 2 diabetes (Diabetologia, 2023)
• Pharmacology, physiology, and mechanisms of incretin hormone action (Cell Metabolism, 2013)
• The expanding incretin universe: from basic biology to clinical translation (Diabetologia, 2023)
• Incretin-based therapies (The Medical Clinics of North America, 2015)
• The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update (Diabetes, Obesity & Metabolism, 2021)
• The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions (The Lancet Diabetes & Endocrinology, 2016)
• Incretin-based therapy of metabolic disease (Danish Medical Journal, 2022)
• Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies (Signal Transduction and Targeted Therapy, 2024)
• Impact of Incretin-Based Therapy on Skeletal Muscle Health (Medicina, 2025)
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (Lancet, 2006)
• Sleep and circadian effects on the incretin system (Current Sleep Medicine Reports, 2025)